Inflammatory markers in cystic fibrosis
References (19)
Antibacterial therapy in cystic fibrosis: A review of the literature published between 1980 and February 1987
Chest
(1988)- et al.
Elastase-a 1 proteinase inhibitor: an early indicator of septicaemia and bacterial meningitis in children
J Pediatr
(1987) - et al.
Granulocyte elastase-a 1 antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections
J Pediatr
(1987) - et al.
Diagnostic criteria for adult respiratory distress syndrome: time for reappraisal
Lancet
(1989) - et al.
Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis
J Pediatr
(1988) A rapid and sensitive solid-phase enzyme immunoassay for C-reactive protein
J Immunol Methods
(1982)- et al.
Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis
Lancet
(1987) - et al.
What is a “pulmonary exacerbation” in cystic fibrosis?
J Pediatr
(1987) Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: Current state of the host-bacterium interaction
J Infect Dis
(1985)
Cited by (53)
C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)
2021, Archivos de BronconeumologiaCitation Excerpt :One of the inflammatory biomarkers most extensively studied is C-reactive protein (CRP).21 An increase in the systemic concentration of this molecule has been associated with greater severity of asthma, COPD, and cystic fibrosis (CF).22–27 However, data on the relationship between the concentration of CRP in clinically stable state and BE is still scarce, particularly with respect to the number and severity of exacerbations.28
Laboratory biomarkers for lung disease severity and progression in cystic fibrosis
2020, Clinica Chimica ActaCitation Excerpt :Reviewed studies with a focus on distinct blood-based biomarkers determined in different patient populations with various clinical utilities are summarized in Table 1. Serum or plasma CRP concentrations as indicators of systemic inflammation in CF have been analyzed since the early nineties of the last century when these were first found to be increased in CF [41]. After a 2 week-intravenous ciprofloxacin administration, serum CRP was significantly reduced compared to pre-treatment values in CF demonstrating its utility in monitoring treatment efficiency as well [41].
RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations
2019, Journal of Cystic FibrosisCitation Excerpt :Systemic monitoring of inflammation via blood sampling is ideal because it has the potential to reflect the status of inflammation throughout the entire lung, and blood is relatively simple to obtain from patients of all ages. Blood-based biomarkers have been studied in CFPE for nearly 3 decades, and have included acute phase reactants, markers of oxidative stress, neutrophil elastase 1-antiprotease complexes [7], lactoferrin [8, 9], calprotectin [10] and other products of inflammation [11]. The gene expression profile of neutrophils has been recently studied in CF by using hybridization-based microarrays [12].
Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations
2013, ChestCitation Excerpt :The use of CRP as a biomarker of CFPE onset was investigated in nine studies, and a statistical analysis was conducted in six of these. Five of the six studies demonstrated a statistically significant increase in CRP levels from the stable to the CFPE state.14,32,33,52,53 Based on a quantitative review of the average and the variability in CRP levels among health states for each study, the average increase appeared to be large, but there was also substantial variation in the average measurements within each health state (e-Table 4).
Mucoid Pseudomonas aeruginosa caused by mucA mutations result in activation of TLR2 in addition to TLR5 in airway epithelial cells
2012, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Therefore signals that increase inflammation in chronically infected CF patients may worsen decline in lung function. Markers of inflammation are increased at the onset of pulmonary exacerbations [3] and following these episodes, a net decline in lung function has been documented from pre-exacerbation state [21]. Unfortunately, very little is known about pulmonary exacerbations.
Circulating markers to assess nutritional therapy in cystic fibrosis
2005, Clinica Chimica Acta